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Abstract
Motivation: One way to identify genes possibly associated with ageing is to build a classification model
(from the machine learning field) capable of classifying genes as associated with multiple age-related
diseases. To build this model we use a pre-compiled list of human genes associated with age-related
diseases and apply a novel Deep Neural Network (DNN) method to find associations between gene
descriptors (e.g. Gene Ontology terms, protein-protein interaction data, biological pathway information)
and age-related diseases.
Results: The novelty of our new DNN method is its modular architecture, which has the capability of
combining several sources of biological data to predict which ageing-related diseases a gene is associated
with (if any). Our DNN method achieves better predictive performance than standard DNN approaches,
a Gradient Boosted Tree classifier (a strong baseline method) and a Logistic Regression (LR) classifier.
Given the DNN model produced by our method, we use two approaches to identify human genes that are
not known to be associated with age-related diseases according to our dataset. First, we investigate genes
that are close to other disease-associated genes in a complex multi-dimensional feature space learned by
the DNN algorithm. Second, using the class label probabilities output by our DNN approach, we identify
genes with a high probability of being associated with age-related diseases according to the model. We
provide evidence of these putative associations retrieved from the DNN model with literature support.
Contact: A.A.Freitas@kent.ac.uk
1 Introduction
An increasing number of researchers are focusing on solving the ‘ageing
problem’, that is, trying to delay ageing in humans. This goal seems
to be more and more plausible in the not so distant future: biologists
can already considerably extend the lifespan of several animal species
such as the fruit fly and the mouse (De Magalhães et al., 2017). Also,
advances in sequencing and analysis have successfully identified several
potentially ageing-related proteins (Tacutu et al., 2018). In addition, some
organisms (including a few animals) seem to have negligible and even
negative senescence (Jones et al., 2014), which indicates that ageing may
not be as inevitable as it was first thought.
Another possible outcome of studying ageing as a whole is to reduce
the incidence of many different age-related diseases at the same time. This
may be more effective than the current approach of treating one disease at a
time and could potentially stop the trend of increasing costs of treating age-
related diseases (Goldman et al., 2013). To this end, instead of focusing on
a single disease, in this work we focus on predicting whether or not human
genes are associated with several age-related diseases at the same time
using Deep Neural Network (DNN) methods. For a review of machine
learning applied to ageing research in general, see (Fabris et al., 2017).
The machine learning field went through an explosion of DNN
applications in the last few years due to the development of new DNN
architectures and algorithms, the availability of powerful and accessible
processing hardware, and the increasing volume of data available to train
the models. The areas of bioinformatics and medicine were no different,
DNNs have been applied to tackle several problems in these fields such as
1
© The Author(s) 2019. Published by Oxford University Press. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the 
original work is properly cited. 
D
ow
nloaded from
 https://academ
ic.oup.com
/bioinform
atics/advance-article-abstract/doi/10.1093/bioinform
atics/btz887/5679772 by guest on 19 D
ecem
ber 2019
2 F. Fabris, Daniel Palmer, Khalid M. Salama, João Pedro de Magalhães and Alex A. Freitas.
MRI image processing (Angermueller et al., 2016), prediction of non-
coding DNA function (Quang and Xie, 2016), and prediction of GO
terms (Kulmanov et al., 2017).
The contributions of this paper are twofold: 1) to propose and evaluate
a novel DNN architecture (using Keras/tensorflow) to predict which age-
related diseases (our class labels) are associated with human genes (our
instances) – note that a gene can be associated with no ageing-related
disease or multiple ageing-related diseases; and 2) based on the output of
the model, to suggest some genes for further investigation. Our proposed
architecture, called ‘Modular DNN’, integrates several data sources to get
the final model’s prediction. We compare the Modular DNN approach with
more traditional deep learning architectures, with a Gradient Boosted Tree
(BT) classifier (lightgbm implementation) and with a traditional Logistic
Regression (LR) classifier in terms of predictive power.
The remainder of this paper is organised as follows: Section 2 describes
how the DNN was constructed and how we compiled our data. Section 3
reports the results of our experiments, including a statistical analysis of
the predictive performance of the DNN, BT and LR classifiers. Section 4
presents a list of promising genes for further analysis according to our
DNN approach. Finally, in Section 5 we conclude our work.
2 Methods
2.1 The Proposed Deep Neural Network
In this work we investigate a deep neural network architecture using
neurons with RELU activation functions and using a stochastic gradient
descent algorithm as the optimization engine. Figure 1 shows a high-
level graphical representation of the proposed architecture. Our Modular
DNN approach comprises several Encoder ‘modules’, one module for each
feature type. Each module can be conceptualised as a supervised feature-
extraction algorithm specialised in extracting new, higher-level, features,
also referred to as embeddings. Embeddings represent high-dimensional
features into dense low-dimensional numerical features.
Each module is trained for a given feature type and is implemented
as a DNN with 3 fully connected layers followed by an output layer that
predicts whether or not each instance (gene) is associated with each of
the class labels (27 age-related diseases). Each gene may be associated
with several class labels at the same time (or none). The hidden layers
contain, respectively 64, 32, and 16 neurons. These 3 hidden layers have
a dropout ratio of 0.5 during the training phase. The output layer of an
Encoder module contains 27 neurons, one for each of the 27 age-related
diseases. The number of trainable weights and neurons in each DNN type
is shown in Table 1.
Note that the predictive performance of the modules can be estimated
independently of one another. This will be shown in the next section. After
each Encoder module is trained, we remove its output layer (predicting the
27 class labels) and use the outputs of its 16 neurons in the third hidden layer
as higher-level features. To combine the individual feature type modules,
the outputs of the third hidden layers of all Encoder modules are combined
and passed to a final module (the Combiner) that makes the final prediction.
The Combiner contains two extra hidden layers, the first one containing
32 and the second one containing 16 neurons.
The number of trainable weights of the non-modular DNNs, which do
not use the combiner module (rows 1 to 5 in Table 1) follows the formula
(nfeats +1)× 64+65× 32+33× 16+17× 27 = (nfeats +1)×
64+ 3067, where nfeats is the number of features in the dataset, shown
in the third column of Table 1. Note that the expression 65× 32 + 33×
16 + 17 × 27 corresponds to the number of neurons in the first hidden
layer plus one for the bias (65) times the number of neurons in the second
layer (32), followed by the number of neurons in the second layer plus one
(33) times the number of neurons in the third layer (16), followed by the
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Fig. 1: Architecture – Gray nodes represent the inputs coming from several
biological databases. Followed by nodes representing the supervised
feature extraction modules. The Combiner joins the higher-level features
coming from the feature extraction modules to make a final prediction
(rightmost node). Each of the encoder nodes, as well as the combiner
node, are deep multi-layer neural networks (DNNs).
number of neurons in the third layer plus one (17) followed by the number
of neurons in the output layer (27).
Similarly, the number of trainable weights in the combiner module of
the modular DNN is (16× 4 + 1)× 32 + 33× 16 + 17× 27 = 9211.
The first term of the sum corresponds to the number of projections features
extracted from the 4 modules (16 features from the last hidden layer of
each one of the GO, PPI, PathDIP and GTex modules, plus one for the bias)
times the number of neurons in the first hidden layer (32), followed by the
number of neurons in the first layer plus the bias (33) times the number
of neurons in the second hidden layer (16), followed by the number of
neurons in the second layer (16) plus the bias times the number of classes
(27). Note that this is the number of trainable weights, in the Combiner
module, after each of the Encoder modules have been trained. The total
number of weights is 9, 211 + ((13, 615 + 1)× 64 + 65× 32 + 33×
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Module(s) # of trainable weights # of input neurons
(number of features)
# of hidden neurons
(in all hidden layers)
# of output neurons
GO 874,491 13615 112 27
PPI 891,899 13887 112 27
PathDIP 309,691 4790 112 27
GTex 8,507 84 112 27
All (concat.) 2,075,195 32376 112 27
Modular DNN 2,091,963 (9,211 for the Combiner module,
2,082,752 for all 4 Encoder modules)
32376 160 27
16)+((13, 887+1)×64+65×32+33×16)+((4, 790+1)×64+
65×32+33×16)+((84+1)×64+65×32+33×16) = 2, 091, 963
Note that each module learns a more compact and richer representation
of the input features, which can be more powerful than the original sparse,
high-dimensional representation of the features. For this reason, our
hypothesis is that combining several specialised modules using a Combiner
achieves better predictive performance than the individual modules and
than a DNN trained concatenating all feature types into a single input
layer. We evaluate this hypothesis in the next section.
We also investigate if sequentially adding modules to the Modular
DNN in a forward greedy manner, the Forward Sequential Selection
Modular DNN approach (FSS Modular approach), achieves better
predictive performance than the modular DNN using all 4 modules. In
this FSS approach the training set is divided into a learning set and an
evaluation set, with 2/3 and 1/3 of the training instances, respectively.
This FSS approach works by initializing the DNN with no modules, then
tentatively testing the performance of the DNN with one module at a time,
re-training the Combiner node and measuring the predictive performance
of the network on the evaluation set. The best single module is permanently
added to the DNN, and the procedure is repeated by tentatively adding one
of the 3 remaining modules at a time to the current DNN, and so on.
The procedure stops if tentatively adding each of the remaining modules
does not increase predictive performance, or of course if all modules were
already added to the DNN.
Our modular approach has 3 advantages when compared to the usual
approach of concatenating all features and training a single classifier: 1) the
possibility of adding new feature types to the predictive model without the
need of re-training the whole model, just the Combiner module; 2) a more
modular, clearer analysis of the effect of each feature type on the predictive
performance of the entire DNN, i.e., as feature types are only ‘mixed’ at
the Combiner module, the effect of the extracted feature types reaching
the Combiner module can be analysed individually in terms of predictive
performance; and 3) reduced memory consumption (the modules do not
need do be loaded into the computer’s memory at the same time).
Our source code, implemented using the Python programming
language and the Keras DNN API is freely available at https://
github.com/fabiofabris/Bioinfo2019
2.2 Dataset Compilation
Human protein coding genes were downloaded from NCBI BioMart v87
and age-related disease gene associations were obtained from (Fernandes
et al., 2016). These disease associations represent an age-related disease
specific subset of the Genetic Association Database (Becker et al., 2004), a
large database of genetic association study results collected until 2014. As
such, a gene having a positive class label for a disease association indicates
that when this database was frozen in 2014, it contained SNPs associated
with the given disease for that gene.
After this list of gene-diseases associations was compiled, we combine
each gene with the 4 feature types used in this work (GO, PPI, PathDIP
and GTex). GO term-gene associations were collected from the NCBI web
site using the following query:
"Homo sapiens"[Organism] AND "source_genomic"[properties]
AND "genetype protein coding"[Properties] AND alive[prop])
PPI data was collected from BioGRID (database version 3.4.146),
and PathDIP information was collected from the PathDIP website
(version 7). Our datasets are available at https://github.com/
fabiofabris/Bioinfo2019.
3 Experiments
3.1 Comparing the Modular DNN approach with the
standard DNN and other methods
In this section, we compare our Modular DNN approach with 5 baselines:
1) the standard DNN (trained using the individual feature types and the
dataset with all concatenated feature types); 2) the Gradient Boosted Tree
(BT) (Ke et al., 2017) algorithm (a state-of-the-art classifier) also using
individual feature types, the concatenated dataset, and a stacking approach.
3) the Forward Sequential Selection (FSS) Modular DNN approach; 4) a
‘Naive’ classifier that ranks the genes in terms of study ‘popularity’ – that
is, more studied genes are ranked as ‘more associated with the diseases’
than less studied genes. For GO, PPI and PathDIP datasets we define ‘study
popularity’ as the number of terms associated with the gene. If the gene is
not present in the dataset at all, the popularity of the gene is ‘0’ by definition.
For the GTex feature type (a unbiased feature) we assume that all genes
present in the dataset have popularity ‘1’, and the genes not present in the
dataset have popularity ‘0’. We also combined the previously described
‘frequency measures’ by adding up all four popularity counts, creating
a fifth ‘naive’ classifier that uses information from all feature types. The
Naive classifier is a useful heuristic to test if the sophisticated classification
algorithms (DNN and BT) are going beyond simply assigning the positive
class label to well-studied genes Gillis and Pavlidis (2011). 5) The Logistic
Regression (LR) classifier from Sklearn using L2 regularisation and default
parameters.
We have estimated the performance of the classification algorithms
using the popular 10-fold cross-validation procedure. This procedure
divides the dataset into 10 folds of approximately equal size. Next, each
fold is used as a validation dataset and the other 9 folds used as the training
dataset. The performance of the classification algorithm is estimated by
averaging the performance in the 10 validation sets. Note that the predictive
performance of each one of the 27 classes is calculated independently using
the AUROC measure and averaged to get the final measure of predictive
performance for the whole model.
Table 2 shows the predictive accuracy results across feature types
and corresponding combination approaches. The first column shows the
feature type or combination approach/method being analysed, with the
sixth and seventh rows showing the proposed Modular and FSS Modular
DNN approaches. The second column shows the percentage of unknown
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Table 2. Comparing AUROC results of our Modular DNN approach (in bold) with the individual feature types and the full dataset concatenating all features (Concat.
all feats.) using the DNN, BT and LR algorithms. This table also shows the results when varying the strategy to deal with “unknown genes” – i.e., genes for which
the values of all features (of a given feature type) are unknown – e.g, a gene where all GO term features have missing values. Columns 3, 5 and 7 show the results
when classifying all genes (including unknown genes) while columns 4, 6 and 8 shows the results when ignoring unknown genes. The last column shows the results
for the ‘Naive’ apporach. For the AUROC results of our approach for the individual diseases, please consult the supplementary file ‘auroc_per_disease.xlsx’.
Feature Type or
Classification
Method/Approach
% of
unknown
genes in the
feature type
AUROC values
DNN BT LR Naive
pred. all
genes
pred. known
genes only
pred. all
genes
pred. known
genes only
pred. all
genes
pred. known
genes only
pred. all
genes
GO 4.0% 0.8498 0.8583 0.8520 0.8468 0.7900 0.7981 0.7995
PPI 19.4% 0.6381 0.6897 0.6585 0.6782 0.6844 0.6889 0.6080
PathDIP 16.8% 0.7535 0.8051 0.8392 0.8314 0.7600 0.7607 0.7817
GTex 4.1% 0.7507 0.7476 0.7156 0.7114 0.7173 0.7233 0.5062
Concat. all feats. 0.0% 0.7548 0.7548 0.8794 0.8794 0.8059 0.8059 0.8105
Mod. approach 0.0% 0.8795 0.8795 NA NA NA NA NA
FSS Mod. approach 0.0% 0.7525 0.7525 NA NA NA NA NA
Stacking 0.0% NA NA 0.7301 0.7301 0.8711 0.8711 NA
genes in each feature type – by unknown gene we mean a gene for which
the values of all features (of a given type) are unknown, because there is no
annotation of that feature type for the gene. For instance, a gene without
any GO term annotations is called an “unknown” gene for that feature type.
Note that the feature type with the largest proportion of unknown genes is
the PPI feature type, with 19.4% unknown genes. The next four columns
present the experimental conditions, as follows. The third column shows
the AUROC for the DNN algorithm when using the class label frequencies
in the dataset as the probabilities of predicting the corresponding classes for
the unknown genes. The fourth column shows the AUROC results for the
DNN algorithm when discarding the unknown genes altogether. The next
four columns show equivalent information for the Gradient Boosted Tree
(BT) and Logistic Regression (LR) algorithms. The last column shows the
results of the Naive approach. Note that the last row shows the result of
a stacking approach (Witten et al., 2016) that consists of training a meta-
level BT or LR using as features the class probabilities output by the 4
base level BTs or LRs trained with the individual feature types.
First, we will analyse the predictive performance of the DNN classifiers
(columns 3 and 4) using 4 types of experimental conditions: a) trained using
one feature type at a time (rows 1 to 4), b) using a full dataset concatenating
all feature types (row 5), c) using our Modular DNN approach (row 6),
and d) using the FSS Modular DNN approach (row 7).
Table 2 shows that our new approach (Modular DNN) achieves better
predictive performance than all other individual feature types, and also
better performance than the FSS Modular approach and the “Concat. all
feats.” approach, which uses a concatenation of all feature types, training a
single large, non-Modular DNN. Also, when using the non-Modular DNN
trained with a single feature type (rows 1 to 4), the AUROC calculated
using only known genes (4th column) is greater than the AUROC when
using all genes (3rd column) in 3 out of 4 cases. The only exception
is the GTex feature type, but the difference is very small (0.0031). This
generally greater AUROC when predicting only known genes is expected,
as removing validation instances representing unknown genes tends to
produce an ‘easier’ classification problem. Note that the Modular DNN
approach classifies all genes and still has better predictive performance
than the approaches that do not classify all genes (including BT and LR
approaches), being clearly superior both in terms predictive power and
classification coverage.
By analysing the learning curves (presented as supplementary material)
we can clearly see that the DNN models learned from the “PPI” and
“Concat. all feats.” datasets are overfitting, i.e., after a certain number
of epochs, the error rate in the testing set starts to increase, whilst the error
rate keeps decreasing in the training set. This overfitting explains why
those feature types had poor predictive performance.
Comparing the results of the Modular DNN and the BT algorithm,
overall, the Modular DNN approach (columns 3 and 4, sixth row) achieves
higher AUROC values than BT across all individual feature types (columns
5 and 6, rows 1 to 4). Comparing columns 3 and 5, we can see that for
the individual feature types (rows 1 to 4), BT achieves higher AUROC
values when using all genes (including unknown genes) than the DNNs
in 3 out of 4 feature types (the only exception is the GTex feature type).
Also, the performance of BT using stacking (last row) is not competitive
in comparison with BT using all features (row 5).
Interestingly, it seems that the BT approach performs worse when the
unknown genes are removed from the validation set. Comparing columns
5 and 6, the AUROC of BT decreased in 3 out of 4 occasions when
discarding unknown genes, performing worse than the DNN in 3 out of
4 cases in this scenario, although the differences are smaller than 0.01 in
all cases. This counter-intuitive result is due to the fact that the positive
class (disease) probabilities the BT algorithm is assigning to the known
genes are in general higher than the probabilities assigned to the unknown
genes (which have a lower disease frequency in the dataset than the known
genes). Hence, the unknown instances are correctly ranked below most
true positives most of the time, which may ‘inflate’ the AUROC results.
As an example, consider an algorithm that randomly assigns high
positive class label (disease) probabilities to the known genes. The AUROC
of this classifier would be 0.5 on average. Next, assume that we assign low
positive class probabilities to the unknown genes (which have a lower
disease frequency in the dataset than the known genes). The final AUROC
of this experiment (combining both sets of predictions) would be higher
than 0.5, as the positive class ‘density’ of the set of known genes is higher
than the positive class ‘density’ of the set of unknown genes.
The LR classifier (columns 7 and 8) had reasonable predictive
performance in some feature types, especially when using the PPI feature
type predicting all genes, where it outperformed both the DNN and BT
algorithms. The best overall performance for the LR algorithm (using the
stacking aproach) is close to the best DNN result (the Modular Approach).
Finally, the Naive approach had considerably worse performance than
the BT classifier across all feature types. The Naive approach outperformed
the DNN in 2 feature types (PathDIP and Concat. all feats.). The Naive
approach also outperformed LR when using two feature types (GO and
PathDIP). However, the best AUROC achieved by the Naive classifier
(0.8105) is considerably inferior to the best AUROC of the Modular
Approach (0.8795).
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53.2 Statistical analysis of the results
In this section, we perform a statistical analysis to compare the
performance of the Modular DNN algorithm with other DNN approaches,
the Gradient Boosted Tree and the Linear Regression classifier across
several feature types considering the approaches that use unknown genes
(third, fifth and seventh columns of Table 2). We do not compare the results
of other columns as the underlying datasets are not the same (they have
different numbers of instances). Also, to save space, we do not show the
results comparing the Modular DNN with the Naive approach since every
test resulted in a p-value very close to zero, - i.e, the Modular approach is
clearly statistically significantly superior to the Naive approach.
We use a Bayesian test of statistical significance and a traditional Null
Hypothesis Significance Testing (NHST), both based on the Wilcoxon
signed rank test. The motivation to use not only the traditional NHST
analysis, but also a more modern Bayesian analysis involves several major
drawbacks of the popular NHST analysis, as discussed in (Greenland et al.,
2016; Goodman, 2008; Stang et al., 2010; Benavoli et al., 2017). For
each algorithm pair we use the paired per-fold AUROC to test if they are
significantly different. Note that the 10 fold are divided always in the same
way, i.e., they contain the same instances across all tests.
Table 3 shows the results comparing the Modular DNN with the other
approaches. The first column shows the baseline being compared to the
Modular DNN (the traditional DNN, the BT or the LR classifiers), the
second column shows the feature type, the third column shows the AUROC
values, the fourth column shows results for the Bayesian test of statistical
significance and the fifth column shows the p-values of the NHST, under
the null hypothesis of equivalency of the classifiers’ AUROCs.
The three values reported in the fourth column of Table 3 represent,
respectively:
1. the probability of the Modular DNN being better than the classifier
learned using the feature type or approach in the first column (the
baseline classifier);
2. the probability of the AUROC of the two classifiers being in the Region
Of Practical Equivalency (ROPE), which means the difference in their
AUROC values is less than 1%; and
3. the probability of the baseline classifier being better than the Modular
DNN classifier.
Overall, the Modular DNN statistically significantly outperformed (at
the significance level α = 0.05) the baseline approaches in every test,
with two exceptions: 1) when using the Gradient Boosted Tree (BT) and
the “Concat. all feats.” dataset, the probability of the Modular DNN being
better than the BT algorithm was 0.1086 according to the Bayesian test,
and the null hypothesis could not be rejected. We could still say that the
Modular DNN is at least equivalent to the BT approach with p = 0.8771
(adding up the p-values for the DNN and ROPE in the 11th row of Table 3);
and 2) when using the LR model and the stacking approach, the probability
of the Modular DNN being better than LR was 0.3920 according to the
Bayesian test. Note, however, that the probability that the LR algorithm is
better than our DNN aproach is low (0.0492).
4 Prioritising Genes for Further Analysis
4.1 Analysing the output of the Modular DNN
In the last step of our analysis, we mapped our instances (genes) into a
16D space by training our Modular DNN using all available instances and
retrieving the 16-dimensional projection of the training instance from the
values output by the 16 neurons of the last hidden layer of the Combiner
module. This dense 16D projection is known as an embedding. Next,
for each class (disease) to be predicted, we multiply each element of the
Table 3. Comparing the Modular DNN approach (AUROC=0.8795) with the
DNN, BT and LR approaches using Bayesian hypothesis testing and the
traditional NHST.
Base. Feature type or
Approach
AUROC Bayesian p-values
(DNN, ROPE, Base.)
NHST p-
values
DNN
GO 0.8498 0.9995, 0.0005, 0.0000 0.0051
PPI 0.6381 1.0000, 0.0000, 0.0000 0.0051
PathDIP 0.7535 1.0000, 0.0000, 0.0000 0.0051
GTex 0.7507 1.0000, 0.0000, 0.0000 0.0051
Con. all feats. 0.7548 1.0000, 0.0000, 0.0000 0.0051
FSS Mod. app. 0.7525 0.9989, 0.0011, 0.0000 0.0069
BT
GO 0.8520 0.9980, 0.0020, 0.0000 0.0093
PPI 0.6585 1.0000, 0.0000, 0.0000 0.0051
PathDIP 0.8392 0.9999, 0.0001, 0.0000 0.0051
GTex 0.7156 1.0000, 0.0000, 0.0000 0.0051
Con. all feats. 0.8794 0.1086, 0.7685, 0.1229 0.8785
Stacking 0.7301 1.0000, 0.0000, 0.0000 0.0051
LR
GO 0.7900 1.0000, 0.0000, 0.0000 0.0051
PPI 0.6844 1.0000, 0.0000, 0.0000 0.0051
PathDIP 0.7600 1.0000, 0.0000, 0.0000 0.0051
GTex 0.7173 1.0000, 0.0000, 0.0000 0.0051
Con. all feats. 0.8059 1.0000, 0.0000, 0.0000 0.0051
Stacking 0.8711 0.3920, 0.5588, 0.0492 0.3863
embedding vector by its corresponding weight in the network edge leading
to the output layer’s node representing that class in the Combiner module.
This final step creates 27 16D vectors for each instance, one vector per
class.
Given these 16D data spaces, for each class (disease), we analysed
the projections of the instances, identifying several clusters of instances
(genes) annotated with a positive class label (i.e., a disease). In some
cases, instances annotated with the negative class label (i.e., not annotated
with the corresponding disease) are also located in these clusters. These
negative instances are clear targets for further analysis since they are ‘close’
to positive instances and could be wrongly annotated in our data. Recall
that negative labels are less reliable (lack of evidence is not the same as
evidence for the absence of disease (Fabris et al., 2018)).
To automatically identify these negative instances, we have proceeded
as follows. For each one of the 27 classes, we have identified all negative
instances that have at least 9 neighbours with the positive class label among
its 10 nearest neighbours in the original 16D space extracted from the DNN
(after multiplying the instance embeddings by the corresponding output
weights). Due to the stochastic nature of the DNN training algorithms, we
repeated this procedure 30 times (varying the random seed), re-training
the Combiner module using a different random seed, and reported the
candidate genes satisfying the 9-neighbours conditions in at least 20 out
of the 30 randomised runs. Most classes did not have any gene with a
negative class label satisfying the “9-positive-neighbours” condition in at
least 20 randomised runs. The condition is satisfied only for the classes
“Associated with Heart Diseases” (2 candidate genes), “Associated with
Myocardial Infarction” (1 candidate gene), and “Associated with Type 2
Diabetes” (3 candidate genes).
Due to space limitations, we show in Table 4 two out of the six
interesting negative instances (genes TGFB1 and IL1B, both neighbours
of many genes annotated with the “Associated with Type 2 Diabetes”
class label). The other 4 instances satisfying the 9-positive-neighbours
conditions are shown as supplementary material. Table 4 consists of two
subtables, each starting with the identifier of the candidate gene (the gene
annotated with the negative class label and having at least 9 positive
neighbours) and the number of times the gene was selected as a candidate
in the 30 randomised runs of the DNN. In the next row we show the
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Table 4. List of negatively labelled candidate genes with at least 9 positive
neighbours annotated with the label ‘Associated with Type 2 Diabetes’
appearing in all 30 runs of the Modular DNN. Each sub-table shows in its
heading the name of the candidate gene and the average, minimum and
maximum positive class label probabilities across the 30 randomised runs. Next,
we show the list of positive neighbours and the list of its negative neighbours
(if any) of the candidate gene. The sub-tables also show the number of times
the gene was in the Nearest Neighbour (NN) list of the candidate gene.
Candidate gene: TGFB1 (transforming growth factor beta 1).
Found in 30 out of 30 randomised runs.
Avg. prob.: 0.4211 / Min. prob.: 0.1257 / Max. prob.: 0.7044
Times in
NN list
Positive neighbouring genes
30 APOA1 (apolipoprotein A1)
30 LEP (leptin)
30 IFNG (interferon gamma)
30 PTGS2 (prostaglandin-endoperoxide synthase 2)
30 VEGFA (vascular endothelial growth factor A)
30 ADIPOQ (adiponectin, C1Q and collagen domain containing)
30 PPARG (peroxisome proliferator activated receptor gamma)
30 APOA4 (apolipoprotein A4)
28 PPARGC1A (PPARG coactivator 1 alpha)
2 CYP1A1 (cytochrome P450 family 1 subfamily A member 1)
Times in
NN list
Negative neighbouring genes
30 IL1B (interleukin 1 beta)
Candidate gene: IL1B (interleukin 1 beta).
Found in 30 out of 30 randomised runs.
Avg. prob.: 0.4954 / Min. prob.: 0.1451 / Max. prob.: 0.8449
Times in
NN list
Positive neighbouring genes
30 APOA1 (apolipoprotein A1)
30 LEP (leptin)
30 APOA4 (apolipoprotein A4)
30 AGT (angiotensinogen)
30 PTGS2 (prostaglandin-endoperoxide synthase 2)
30 VEGFA (vascular endothelial growth factor A)
29 IFNG (interferon gamma)
27 TNF (tumor necrosis factor)
26 APOE (apolipoprotein E)
8 ADIPOQ (adiponectin, C1Q and collagen domain containing)
Times in
NN list
Negative neighbouring genes
30 TGFB1 (transforming growth factor beta 1)
average, minimum and maximum positive class label probabilities across
the 30 runs of the algorithm. Next, we show a list of the candidate gene’s
neighbours annotated with the positive class label, followed by the list of
neighbours annotated with the negative class label, both with the number
of times the gene was in the Nearest Neighbour (NN) list of the candidate
gene across the randomised experimental runs.
Summarizing Table 4, our analysis suggests that the genes TGFB1 and
IL1B are good candidates for association with type 2 diabetes. In fact, both
TGFB1 and IL1B genes are established to be involved in the pathogenesis
of diabetic nephropathy (Chang et al., 2016; Stefanidis et al., 2014). IL1B
in particular, has previously been associated with coronary heart disease
in some genetic backgrounds (Rai et al., 2016), which in turn shares many
genetic pathways with type 2 diabetes and may share associated genetic
variants (Zhao et al., 2017).
4.2 Analysing the probabilities output by the Modular DNN
We present in Table 5 the top-5 negative genes in terms of average
probability of being associated with a positive class label by our Modular
DNN algorithm across 30 randomised runs. Due to space limitations, we
present only the results for brain diseases, neoplasms and myocardial
infarction, which are the most interesting results. The full results are
presented as supplementary material. We have repeated the experiment
30 times due to the stochastic nature of the DNN training algorithm. Note
that negative genes predicted with a relatively high positive class label
probability are clear candidates for further analysis.
Table 5 shows 3 sub-tables, each sub-table shows in its header the class
label under consideration and the 99% percentile of the probability that
the gene belongs to the positive class (i.e. 99% of the genes have a lower
average positive class label probability than the one shown). Note that
the probabilities of the genes in the table are much greater than the 99%
percentile probability, meaning that these probabilities are much greater
than the vast majority of the probabilities output by the classifier. Each sub-
table shows in its first column the gene identifier and name. The second,
third and fourth columns show, respectively, the average, minimum, and
maximum probabilities across the 30 randomised runs of the DNN.
Table 5. List of the top-5 negative genes in terms of average positive class label
probability across 30 randomised runs of the modular DNN and three disease
types. The table shows the class label associated with the gene, the average,
minimum and maximum probabilities across the 30 runs.
Candidate gene Avg. prob. Min. prob. Max. prob.
Brain disease (99% percentile of avg. prob.: 0.0942)
AGT (angiotensinogen) 0.5764 0.2659 0.8631
LEP (leptin) 0.4762 0.2315 0.7186
APOA4 (apolipoprotein A4) 0.4737 0.2214 0.7014
PTGS2 (prostaglandin-endoperoxide
synthase 2)
0.4393 0.2052 0.6542
TGFB1 (transforming growth factor beta
1)
0.4306 0.1977 0.6367
Neoplasm (99% percentile of avg. prob.: 0.0784)
AGT (angiotensinogen) 0.5128 0.1728 0.8357
APOA4 (apolipoprotein A4) 0.4228 0.1439 0.6891
APOA1 (apolipoprotein A1) 0.3610 0.1338 0.5780
ADIPOQ (adiponectin, C1Q and
collagen domain containing)
0.3507 0.1243 0.5686
APOB (apolipoprotein B) 0.2856 0.1036 0.4588
Myocardial Infarction (99% percentile of avg. prob.: 0.0808)
TNF (tumor necrosis factor) 0.5283 0.1279 0.8312
LEP (leptin) 0.4138 0.1050 0.6374
IFNG (interferon gamma) 0.3532 0.0888 0.5545
PPARGC1A (PPARG coactivator 1
alpha)
0.3050 0.0734 0.4603
CYP1A1 (cytochrome P450 family 1
subfamily A member 1)
0.2844 0.0736 0.4284
There is biological plausibility for the top gene-disease associations
for each disease in Table 5: the gene AGT (angiotensinogen) is implicated
in both Alzheimer’s disease (Mateos et al., 2011) and breast cancer (Herr
et al., 2008), with evidence that the renin-angiotensin system of which
it is a part may be closely involved in cancer processes (Wegman-
Ostrosky et al., 2015) and may even be a target for the treatment of
cancer (Vallejo-Ardila et al., 2018). The gene TNF (tumor necrosis factor)
is expressed in the myocardium in response to mechanical overload or
ischemic injury (Kurrelmeyer et al., 2000), while inhibition therapy of TNF
may reduce the risk of myocardial infarction in patients with rheumatoid
arthritis, a typically high risk group (Low et al., 2017). Interestingly, due
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by our analysis in the previous section.
5 Conclusion
Overall, in terms of predictive performance, the Modular DNN approach
performed better than using individual feature types and using all features
at the same time without the modular architecture (the “Concat. all feats.”
approach). Also, the Modular DNN outperformed the Gradient Boosted
Tree approach and the Linear Regression classifier in both the individual,
‘Concat. all feats.’ and ‘stacking’ feature settings.
Also, we presented two ways of extracting useful information from
DNN models. First, for each negative instance (human gene) we extracted
the neighbouring genes by treating the output of the last hidden layer
of the DNN as a mapping to a 16-dimension space. Next, the negative
human genes in a neighbourhood with at least 9 out of 10 genes were
considered good candidates for further analysis. The second approach
identified the negative genes with high positive probability for the disease
class labels according to the DNN model, which are also candidates for
further analysis.
We conclude that both approaches uncovered genes with biological
plausibility of being associated with some age-related diseases. However,
both approaches result in different candidate genes, which suggests the
complementarity of both approaches and that they should be used in concert
while looking for candidate genes for further analysis. As future work, we
plan to use these genes in conjunction with the human diseasome (Goh
and Choi, 2012) to suggest drugs that target highly ranked candidate genes
and also try to identify functional modules in the candidate gene list. We
also plan to break down the analysis of the results by gene category, for
instance, genes associated with certain biological pathways in all four
individual feature types. This may help identify larger groups of genes
that are clearly associated with the diseases.
Note that the genes identified in our analysis are highly studied.
This is expected, as popular genes tend to have more annotations, and
consequently, more opportunity to posses a property that is strongly linked
to ageing-related diseases. To attenuate this, we plan as future work to use
only feature types (such as levels of gene expression) that are not influenced
by the ‘study popularity’ of the gene.
In particular, according to our projection approach, genes TGFB1
and IL1B are good candidates for association with type 2 diabetes.
Furthermore, according to the approach that investigates negative genes
with high positive probability as output by the DNN, the gene AGT
is associated with brain diseases and neoplasms; and the gene TNF is
associated with myocardial infarction. We found supporting literature for
all these associations, which suggests that although genes are not annotated
with the aforementioned diseases in our dataset, there may be evidence on
the contrary.
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